Pharmaceutical innovation between scientific opportunities and economic constraints

Drug Discovery Today

Volumn 2, Issue 9, 1997, Pages 365-372

  Drews, Jürgen ^a   Ryser, Stefan ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COST; DRUG DEVELOPMENT; DRUG RESEARCH; EXPECTATION; MARKET; PROFIT; REVIEW;

EID: 0030879779     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(97)01086-6     Document Type: Review

References (12)

1. Drews, J. (1996) Nat. Biotechnol. 14, 1516-1518
2. Drews, J. and Ryser, S. Nat. Biotechnol. (in press)
3. Drews, J. in The Genetic Basis of Human Disease: Proceedings of the Scientific Symposium, October 2-6, 1996 in Basel (Ex Libris Roche), Blackwell Science (in press)
4. Mossinghoff, G.J. (1995) Drug Inf. J. 29, 1077-1099
5. Schwartz, H. (1997) Scrip Magazine March, 15-16
6. DiMasi, J.A. et al. (1991) J. Health Econ. 10, 107-142
7. Hansen, R.W. (1979) The Pharmaceutical Development Process: Estimates of Current Development Costs and Times and the Effect of Regulatory Changes (Issues in Pharmaceutical Economics) (Chien, R.I. et al., eds), Lexington Books
8. Wiggins, S.N. (1987) The Cost of Developing a New Drug Pharmaceutical Manufacturers Association, June, Washington, DC, USA
9. Sustaining Innovation in US Pharmaceuticals: Intellectual Property Protection and the Role of Patents (January 1996), The Boston Consulting Group
10. Vasella, D. (1997) Nat. Biotechnol. 15, 485
11. Med. Advertis. News (May 1996) 15 (5), 21-22
12. Lifton, R. in The Genetic Basis of Human Disease: Proceedings of the Scientific Symposium, October 2-3, 1996 in Basel (Ex Libris Roche), Blackwell Science (in press)